Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. BioCancell's leading drug, BC-819, is a double stranded DNA plasmid construct that incorporates the gene for diphtheria toxin (DTA) under the regulation of the promoter sequence for H19 gene. Pursuant to U.S. FDA approved protocols, BioCancell is conducting phase II/b clinical trials for the treatment of pancreatic cancer and for superficial bladder carcinoma cancer, as well as a phase I/IIa clinical trial for the treatment of ovarian cancer.
Tikcro is headquartered in 16 Hatidhar St., PO 4131, Raanana 43665, Israel.
www.tikcro.com/asp/main.html